ロード中...
Epigenetic Therapies in MDS and AML
The use of low dose hypomethylating agents for patients with myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia (AML) has had made a significant impact. In the past, therapies for these diseases were limited and patients who elected to receive treatment were subject to highly toxic,...
保存先:
主要な著者: | , |
---|---|
フォーマット: | Artigo |
言語: | Inglês |
出版事項: |
2013
|
主題: | |
オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4086806/ https://ncbi.nlm.nih.gov/pubmed/22956506 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/978-1-4419-9967-2_13 |
タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|